Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated to developing RNA-based innovative therapies, today announced the successful dosing of the first patient in ...

Shares of TransCode Therapeutics stock opened at $3.85 on Wednesday. The business has a fifty day simple moving average of $395.55 and a 200-day simple moving average of $565.72. TransCode ...

BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to more effectively treating cancer using RNA ...

BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced ...

BOSTON - TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a micro-cap biotech company with a market capitalization of $3.3 million and trading near its 52-week low, has received approval from its Safety ...

TransCode Therapeutics (RNAZ) announced that the Safety Review Committee, or SRC, monitoring its Phase 1 clinical trial has unanimously approved opening of the third cohort of patients based on ...

BOSTON - TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a micro-cap biotech company with a market capitalization of $3.3 million and trading near its 52-week low, has received approval from its ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--SiteOne Therapeutics, Inc., a biopharmaceutical company developing selective ion channel modulators for the treatment of pain, cough, and other ...

Shares of CRISPR Therapeutics have struggled amid less-than-stellar sales of its Casgevy therapy. The company's gene-editing biotechnology holds much promise but still faces significant uncertainties.